Israel’s Teva Pharmaceutical Industries Ltd, said on Dec. 22 it had agreed to pay $519 million to settle charges it violated the U.S. Foreign Corrupt Practices Act.
The settlement with the Department of Justice and the Securities and Exchange Commission relates to conduct in Ukraine, Mexico and a guilty plea by a subsidiary in Russia, and followed a voluntary investigation, Teva said.
